Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
CureVac Stock Quote


Price as of July 15, 2024, 4:00 p.m. ET

CureVac Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
CVAC -63.60% -94%
S&P +24.51% +86.32% +13.24% +66%

CureVac Company Info

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

News & Analysis


Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.